Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 7707 results

  1. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development [GID-TA10553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development [GID-TA10573] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development [GID-TA10623] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development [GID-TA10604] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development [GID-TA10250] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development [GID-TA10664] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development [GID-TA10684] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development [GID-TA10685] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development [GID-TA10662] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development [GID-TA10665] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. eXroid for internal haemorrhoids

      Status ...

    Medical technologies guidance
    Topic selection

  12. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Respirasense

      Status ...

    Medical technologies guidance
    Topic selection

  14. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517

      Status ...

    Technology appraisal guidance
    Topic selection